Status:
COMPLETED
Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.
Detailed Description
Observational prospective study Purely descriptive
Eligibility Criteria
Inclusion
- Patients who:
- Are active RA patients (as judged by treating MD)
- Are 18 years of age or older at time of consent
- Are scheduled by their rheumatologist to initiate SC anti-TNF-α therapy + MTX
Exclusion
- Use of biologics (or any experimental drug) in the last 3 months before initiation of SC anti-TNF-α therapy.
- Participation in other clinical or observational trials
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT01521884
Start Date
November 1 2010
End Date
February 1 2014
Last Update
February 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Gasthuisberg
Leuven, Belgium, 3000